Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, et al. Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018;10(431): eaam8460.
Weïwer M, Xu Q, Gale JP, et al. Functionally biased D2R antagonists: Targeting the β-arrestin pathway to improve antipsychotic treatment. ACS Chem Biol. 2018;13(4):1038–1047.
Krainz T, Gaschler MM, Lim C, et al. A mitochondrial-targeted nitroxide is a potent inhibitor of ferroptosis. ACS Cent Sci. 2016;2(9):653–659.
Joshua Sacher, Ph.D.
Joshua Sacher is a research scientist II in the Stanley Center for Psychiatric Research and the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard, working under the direction of Michel Weïwer and Carol Mulrooney. Sacher leads the Stanley Center’s project investigating selective calcium channel modulators as a potential therapy for schizophrenia. His specific tasks include providing cheminformatics support as part of CDoT’s discovery solutions & systems team. He also is involved in mentorship of graduate, undergraduate, and high school interns.
Sacher received his B.S. in biochemistry from the University of Delaware and obtained his Ph.D. in chemistry at Pennsylvania State University under the supervision of Steve Weinreb. His postdoctoral training in chemistry was undertaken at the University of Pittsburgh in the lab of Peter Wipf. He joined the Broad Institute in 2014.
Contact Joshua Sacher via email at email@example.com.